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Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold
standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to
establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients
treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate effi-
cient dose-finding.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
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Lung cancer is the leading cause of cancer mortality worldwide,
with over 46,000 new cases diagnosed annually in the UK alone [1]
and the incidence is projected to increase, excluding any pending
screen-detected caseload [2,3]. The majority of cases are non-
small cell histology (NSCLC), and approximately one quarter of
patients present with stage III tumours [4].
Concurrent chemoradiotherapy (CRT) is recommended for fit
patients with unresectable stage III disease [5]. Despite advance-
ments in radiotherapy (RT) technology, 5-year survival remains
low at approximately 32% [6]. Cytotoxic systemic anti-cancer ther-
apy (SACT) concurrently with RT is not deliverable for the majority
of patients due to tumour bulk or poor fitness [7] and is delivered
sequentially rather than concurrently for almost two-thirds of UK
cases [8]. Sequential treatment is associated with 5-year survival
rates of only 10%, largely owing to higher rates of loco-regional fail-
ure [5].
Since RT dose escalation has failed to improve outcomes in
locally advanced disease (LA-NSCLC), investigations of intensified
schedules [9,10], improved conformality [11,12] and consolidative
immunotherapy [13] have been undertaken recently. While the
biology underpinning the intrinsic radioresistance of NSCLC
remains incompletely defined, repair of radiation-induced DNA
damage is considered a fundamental component [14]. These path-
ways are actionable [15–18]: potent novel agents targeting DNA
damage response pathways are becoming clinically available [19]
and strategies for synergistic combination of systemic agents with
RT are being realised across tumours [20–24]. Careful, efficient and
multidisciplinary clinical trial design is essential for accurate
assessment of the toxicities associated with these new and chal-
lenging treatment paradigms, and to ensure that the maximum
impact on therapeutic index is achieved [25,26].
The CONCORDE trial is, to our knowledge, the first phase I plat-
form study for the safety assessment of multiple novel drug-RT
combinations in LA-NSCLC and aims to inform how DNA damage
response inhibitors (DDRi) can be combined with radical RT in
patients unfit for concurrent CRT [27]. Five components of the
DNA damage signalling pathway will be targeted using novel sys-
temic agents, in combination with the international RT dose frac-
tionation of 60 Gy delivered in 2 Gy once-daily fractions [6].
To exploit the rapid proliferation rates, aberrant DNA repair and
reliance on the G2/M checkpoint commonly observed in NSCLC, we
aim to evaluate DDRi directed at PARP, ATR, Wee1, ATM and DNA-
PK in the first instance [28]. As non-malignant cells possess a func-
tional G1/S checkpoint, in contrast with most NSCLC, it is proposed
that selective tumour radiosensitisation can be achieved by abro-
gation of the G2/M checkpoint.
The potential targets are extensively reviewed as radio-
sensitisers in Chalmers et al [26] but are briefly summarised here.
PARP (poly-ADP ribose polymerase) enzymes are involved not
only in repair of single strand DNA breaks but are key regulators
of DNA damage repair [29]. Most clinical evidence for PARP inhi-
bition is in the setting of BRCA-mutant malignancies [30–32], but
early-phase trials in combination with radiotherapy for head/neck
cancer were encouraging [33] and studies are planned in glioblas-
toma [20]. The ATR (ataxia telangiectasia and Rad3 related) and
ATM (ataxia telangiectasia mutated) kinases are reportedly cru-
cial for the repair of double-strand DNA breaks and are attracted
to the break sites to enable homologous recombination [29].
Wee1 is a negative regulator at the G2-M checkpoint amongst
other DNA damage response duties [29]. DNA-PK (DNA-
dependent protein kinases) protect exposed DNA strands and so
are particularly important in the non-homologous end joining
DNA repair process [29].62Candidate compounds have been selected based on their dose
enhancement factors in preclinical NSCLC models and emergent
clinical data from other tumours, either as single agents or in com-
bination with radiation and/or cytotoxic chemotherapy [33–35].
Given the significant diversity displayed in radiosensitising activity
and effects on normal tissues [36], which are both dose and sched-
ule dependent, the CONCORDE study has been designed to min-
imise risks and maximise clinical benefits. We will employ
cautious drug dose escalation, careful adherence to organ at risk
dose constraints and a Time To Event Continual Reassessment
Method (TiTE-CRM) model to capture late toxicity whilst allowing
efficient recruitment and dose escalation across five treatment
arms, incorporating a concurrent control arm.2. Methods
2.1. Study design
CONCORDE was developed by a national collaborative of clini-
cians, scientists, biostatisticians and industrial partners, under
the auspices of the National Cancer Research Institute (NCRI) Clin-
ical and Translational Radiotherapy Research Working Group
(CTRad) and the NCRI Lung Group, with patient and public involve-
ment embedded from study conception. The trial is sponsored by
University of Leeds (MO20/118073) and funded by Cancer
Research UK (A28890) and industry partners. The study complies
with Research Governance Framework for Health and Community
Care, the British Good Clinical Practice regulations and the Declara-
tion of Helsinki, and is registered on the European Clinical Trials
Database (EudraCT No 2020-000206-28).
CONCORDE is a randomised, open-label, phase Ib, multi-
institution, multi-arm clinical trial seeking to determine the safety
profile of multiple DDRi agents in combination with fixed-dose
radical RT in LA-NSCLC (see Fig. 1). The platform nature engenders
clinical trial efficiency with multiple parallel arms running simul-
taneously for different investigational medicinal products (IMPs).
Accommodating the collection of side effects at later time points
whilst avoiding stagnancy in accrual, use of the TiTE-CRM will fur-
ther enhance study yield through continued enrolment while pre-
vious patients remain under follow-up [37]. CONCORDE integrates
a calibration/control cohort of patients treated with RT alone to
ensure that the safety data in the combination arms are inter-
pretable. Eligibility criteria are listed in Table 1.2.2. Study objectives and end-points
Primary objective:
 Assess the safety and determine the recommended phase II
dose (RP2D) of each DDRi used in combination with radical RT
for patients with LA-NSCLC. The RP2D will be the dose level at
which it is estimated that 25% subjects will experience dose
limiting toxicities (DLT) (see Table 2) during the 13.5 month
period from the start of RT
Secondary objectives include the description of:
 Safety profile (acute and late) using CTCAE v5.0 [41] and PROMs
[42,43]
 Treatment adherence for each DDRi in combination with RT
 Overall radiotherapy treatment time
 Best overall response using RECIST 1.1 criteria [44]
 Progression free survival (PFS) using RECIST 1.1 criteria [44]
 Overall survival
Fig. 1. CONCORDE study summary.
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 Identify candidate biomarkers that could help select patients
most likely to benefit from a combination of a specific DDRi
and RT
 Investigate if imaging or circulating biomarkers of normal tissue
damage could predict toxicity from DDRi-RT combinations early
 Investigate the impact of therapy with DDRi-RT combinations
on the interplay between tumour and immune system
2.3. Radiotherapy
Patients will be planned using a 4D-computed tomography (CT)
planning scan with intravenous contrast. Target volume delin-63eation will be performed according the ICRU 62 guidance [45]. A
motion-adapted gross tumour volume will encompass identifiable
tumour and ‘CT/positron emission tomography (PET) positive’ lym-
phadenopathy. A 5 mm isotropic margin will be applied for the
internal target volume and a further 5 mmmargin for the planning
target volume.
Treatment will be delivered with intensity modulated RT (>5-
field) or volumetric modulated arc therapy and daily online
cone-beam CT image guidance. RT will commence 7 days after
the first dose of IMP and the total dose will be 60 Gy in 30 daily
2 Gy fractions over a period of 40 days based on EORTC and ICRU
recommendations [46,47]. The moderately hypofractionated
regime commonly employed in the UK [48] was not chosen for
the trial in order to minimise the possibility of acute normal tissue
Table 2
Overview of dose-limiting toxicities.
Non-Haematological Pneumonitis grade  4, or grade  3 for > 7 days
Oesophagitis grade  4, or  3 for > 7 days
Grade  3 nausea, vomiting or diarrhoea despite
optimal medical management
MRC dyspnoea score > 2 grades above baseline/
CTCAE dyspnoea grade  3 for > 7 days
Significant cardiac arrhythmia
Any toxicity leading to interruption of RT for > 4
consecutive doses
Haematological Neutropenia grade  4, or  3 with fever > 38.5 C, or
grade  3 for > 7 days
Thrombocytopenia grade  4, or grade  3
for > 7 days or requiring transfusion
Anaemia grade  3 or requiring a blood transfusion
Other DLTs specific to particular DDRi agents as listed in the
relevant study arm protocol
Any other event, in the opinion of the SRC that is
considered to be clinically significant and related to
trial treatment
Table 1
Inclusion and exclusion criteria for CONCORDE.
Inclusion Criteria Exclusion Criteria
 Histologically or cytologically confirmed NSCLC
 Unsuitable for concurrent CRT/surgery due to
tumour or patient factors
 Stage IIB and IIIA/IIIB (TNM 8 [38]) planned to
receive radical RT +/- induction SACT
 <8 weeks from previous SACT to the start of RT
 Life expectancy estimated to be >6 months
 Performance status (ECOG [39]) 0 or 1
 Medical Research Council (MRC) dyspnoea score
[40] < 3
 Forced expiratory volume in 1 s  40% predicted
 Diffusing capacity of the lungs for carbon monox-
ide  40% predicted
 No prior thoracic RT (excluding breast RT, providing
minimal overlap in RT volumes)
 Adequate haematological, hepatic and renal
function
 Mixed non-small cell and small cell tumours
 Progressive disease during induction SACT
 Participation in a study of an investigational agent/device < 4 weeks prior to treatment
 Current/previous malignant disease which may impact on estimated life expectancy
 History of interstitial pneumonitis
 Prior treatment with pneumotoxic drugs within 1 year, or nitrosoureas with lung toxicity
 Received a prior autologous or allogeneic organ or tissue transplantation
 Cardiac history including uncontrolled ventricular arrhythmia, uncontrolled hypertension, uncontrolled
atrial fibrillation, myocardial infarction within 3 months or long QT syndrome
 Patients unable to swallow orally administered medications or chronic gastrointestinal disease likely to
interfere with absorption of IMP in the opinion of the treating investigator
 Prior RT where there is concern that the proposed treatment volume would overlap with a previously
irradiated volume
 Peripheral sensory neuropathy  grade 2
 Active or prior documented autoimmune or inflammatory disorders
 Exclusions as described in the relevant study arm protocol
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will be conducted through the UK National RT Trials Quality Assur-
ance team. RT dosimetry and treatment data will be collected on all
patients participating in the trial. Treatment start/stop rules are
listed in Table 3.
2.4. Systemic therapy
Consented patients will be randomised between DDRi with RT
or RT alone, on a 3:1 basis, meaning a maximum of 30 patients will
be recruited to each experimental arm, with 10 controls each.Table 3
A summary of start/stop rules during treatment toxicity.
Scenario Action
RT is suspended for RT-related
toxicity
DDRi will be suspended until RT re-
starts
RT is interrupted for logistical
reasons (e.g. Linac breakdown)
DDRi will be continued during the
interruption
RT is suspended for > 4 consecutive
doses due to RT-related toxicity
(DLT)
No further treatment with DDRi;
RT will resume following toxicity
resolution
DDRi is suspended due to DDRi-
related toxicity with no increased
RT-related toxicity
RT can continue;
DDRi may be re-started at the next
dose level down on resolution of
toxicity to  grade 1 or discontinued
if assigned to dose level 1
64Patients receiving RT alone will be pooled across arms as controls
to provide contemporary toxicity data (50 patients for 5 treat-
ment arms). DDRi therapy will be administered during the week
before RT commences through to the end of RT or shortly after.
DDRi schedules may vary between study arms e.g. intermittent
dosing (such as alternate days). Induction SACT is permitted prior
to trial enrolment but must be complete within 8 weeks of begin-
ning RT. Consolidation immunotherapy will not be given at the
start of the platform as the safety and efficacy in the setting of
sequential chemoradiotherapy or radiotherapy alone is still being
established (for example in PACIFIC-6 NCT03693300). However
the platform is deliberately designed to adapt to changing stan-
dards of care, and may evaluate the safety of DDRi-RT and adjuvant
immunotherapy combinations within its life-span.2.5. Dose escalation
Toxicity will be assessed throughout treatment according to
CTCAE V5 with weekly assessments until  grade 2 toxicities have
resolved to grade 1. DLTs will be monitored for up to 13.5 months
post-start of RT in order to capture both the acute and long-term
toxicities, subdivided into a ‘short DLT period’ and ‘long DLT
period’:
 The short DLT period comprises DDRi and/or RT and up to
4.5 months from the start of RT. It is weighted for 90% in
TiTE-CRM model, as 90% events are expected in this timeframe
 The long DLT period comprises 4.5 to 13.5 months from start of
RT and will allow capture of later-onset DLTs. This long DLT per-
iod will be weighted as 10% in the model.
There will be pre-specified dose levels, including a 1 level for
de-escalation if required. Each patient’s dose will be decided indi-
vidually based on accumulated data available at the time of
recruitment within the TiTE-CRM model. A separate, independent
TiTE-CRM model will be used for each DDRi, with drug dose esca-
lation decisions driven by the occurrence of DLTs and review by the
safety review committee (SRC), chaired by an independent Tho-
racic Radiation Oncologist, and with independent clinicians, statis-
ticians and patient representatives as key members. The pre-
specified dose levels are based on existing early phase data in other
disease sites. Escalations may consist of changes in either dose or
schedule. Holds to recruitment and/or tightening of dose con-
straints to organs at risk may be advised by the SRC if required
to evaluate potential excess toxicity.
Escalation of dose will be restricted until at least one patient has
been followed up through the short DLT period. If the dose is
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imately one patient per month, for at least the first 3 patients
recruited, and additional pauses will be implemented prior to dose
re-escalation. If the lower limit of the credible interval for the esti-
mated probability of unacceptable toxicity is > 0.3 at dose level 1,
or more than three DLTs are observed, that arm will be closed. If no
DLTs are seen at any dose level, that trial arm will close to recruit-
ment once 10 patients have completed the late DLT assessment
period at the highest dose level, and that dose level will be deemed
the RP2D.
2.6. Follow-up
Patients will be followed up until 2 years after the end of RT.
Response to treatment and PFS will be assessed by CT at 1 month
following completion of RT and subsequently at 3, 6, 12, 18 and
24 months, according to RECIST 1.1 where possible [44]. Robust
patient reported outcome measures will be captured with vali-
dated questionnaires (EORTC-QLQ C30, EORTC-QLQ-LC29), and
additional items from the EORTC-QLQ Item Library to cover poten-
tial novel agent toxicities, before randomisation, immediately
post-treatment and during follow-up [42,43].
2.7. Translational research
Patients will be consented for collection of residual archival
tumour at baseline and disease progression for molecular analysis.
Blood will be taken regularly for cfDNA analysis, T-cell repertoire
analysis and circulating markers of cardiopulmonary toxicity.
Imaging datasets including diagnostic imaging, planning scans,
cone-beam imaging and response assessment scans will be col-
lected for subsequent analysis.3. Discussion
Despite RT offering the only curative option for a considerable
proportion of patients with lung cancer, 5-year survival rates are
dismal [5]. The investigation of drugs with synergistic potential
in combination with RT has been neglected historically, due to
the complexity of the necessary trials and a paucity of supporting
preclinical data [49]. Conventional study designs are poorly suited
to addressing such research questions [50]. Radiosensitisation with
novel agents has significantly improved prognosis in a limited
number of other tumours [51,52], but such clinical benefit has
not been demonstrated in the lung cancer population.
CONCORDE is the first platform trial of novel systemic treat-
ment and RT in lung cancer patients [27]. As repair of
radiation-induced DNA damage is thought to enable tumour cells
to survive therapeutic radiation doses, there is a sound scientific
rationale for the combination with DDRi, with supportive preclin-
ical data [15–18]. Related translational research will exploit the
rich, prospective datasets generated, spanning tissue- and
plasma-based genomics, immunobiology, biochemical pathology
and radiomics.
This unique study is the result of close interdisciplinary work-
ing on a national level, most notably between oncology, biostatis-
tics, science and industry. CONCORDE embodies the
recommendations published in the NCRI CTRad consensus state-
ment [25]. Furthermore, the novel multi-arm multi-stage trial
infrastructure means that future patients wishing to participate
in CONCORDE will benefit from up-to-date standard of care treat-
ment as it evolves [53]. Standardised, state-of-the-art and contem-
porary RT within CONCORDE will provide the opportunity to
comprehensively assess normal tissue toxicity in context, and ran-
domisation will ensure that safety data are interpretable.65The CONCORDE platform provides a unique and hypothesis-
driven opportunity to characterise the toxicity profile of novel
radiosensitising drugs in NSCLC. It is anticipated that RP2Ds gener-
ated will enable the investigators to take candidate agents forward
to dedicated randomised studies, and provide insights into the
biology of radioresistance. The approach lends itself to future stud-
ies of novel drug-RT combinations, in NSCLC and other tumours.
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